Granulomatosis with Polyangiitis (GPA) is a type of vasculitis that usually affects the upper airways, lungs and kidneys. Granulomatosis with Polyangiitis (GPA) is a disease that belongs to a group of ...

Eosinophilic Granulomatosis With Polyangiitis (EGPA) is a rare, complex vasculitic disorder that typically presents in patients with a history of asthma and marked eosinophilia. Characterised by ...

Please provide your email address to receive an email when new articles are posted on . Systemic corticosteroid use decreased with mepolizumab treatment. Mean daily oral corticosteroid use fell by 18% ...

Patients with granulomatosis with polyangiitis (GPA) who scored high on a sinonasal symptom test are nearly three times as likely to relapse, according to a new study. These patients reported higher ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

The FDA has approved an expanded indication of AstraZeneca’s benralizumab (Fasenra) in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare, ...

Please provide your email address to receive an email when new articles are posted on . Patients began with mepolizumab or benralizumab before switching to continuing with benralizumab at week 52.

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...

EGPA is an extremely rare disease that causes inflammation of your blood vessels. It can damage small and medium-sized blood vessels. Doctors also call it Churg-Strauss vasculitis, eosinophilic ...

During weeks 48 through 52, a 100% reduction in the OCS dose was observed in 41% of benralizumab-treated patients vs 26% of mepolizumab-treated patients. The Food and Drug Administration (FDA) has ...